Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Pharmacogenomics. 2010 Apr;11(4):481-5. doi: 10.2217/pgs.10.10.
The past decade has seen major advances in our understanding of genomics, with the development of newer and refined technologies. Improvements in the sensitivity and precision of DNA microarrays coupled with the emergence of massively parallel sequencing techniques have redefined how we interrogate the human genome. These tools have facilitated rapid biomarker discovery, uncovered novel targets for therapeutic intervention and enabled mechanistic studies that have helped unravel the mode of drug action. The assessment of drug toxicity based on genomic signatures associated with disease and high-throughput screening for polymorphic interindividual variability in drug responses are procedures that have greatly aided the quality of patient care. The integration of pharmacogenetic approaches for therapeutic monitoring, and health management approaches for advance clinical treatments, will be based on unique patient phenotype profiles and aimed at minimizing adverse drug reactions. In this brief commentary, the evolution and development of key genomics technologies over the past decade is reviewed.
过去十年，我们对基因组学的理解取得了重大进展，出现了更新、更精细的技术。DNA 微阵列的灵敏度和精度的提高，以及大规模平行测序技术的出现，重新定义了我们研究人类基因组的方式。这些工具促进了快速生物标志物的发现，为治疗干预提供了新的靶点，并使机制研究得以进行，有助于揭示药物作用模式。基于与疾病相关的基因组特征评估药物毒性和高通量筛选药物反应中的个体间多态性，极大地提高了患者护理质量。整合治疗监测的药物遗传学方法和临床治疗的健康管理方法，将基于独特的患者表型谱，并旨在最小化药物不良反应。在这篇简短的评论中，回顾了过去十年中关键基因组学技术的演变和发展。
